BR0312995A - Formulação farmacêutica oral sob a forma de uma pluralidade de microcápsulas, permitindo a liberação prolongada de princìpios(s) ativo(s) pouco solúvel(is) - Google Patents

Formulação farmacêutica oral sob a forma de uma pluralidade de microcápsulas, permitindo a liberação prolongada de princìpios(s) ativo(s) pouco solúvel(is)

Info

Publication number
BR0312995A
BR0312995A BR0312995-0A BR0312995A BR0312995A BR 0312995 A BR0312995 A BR 0312995A BR 0312995 A BR0312995 A BR 0312995A BR 0312995 A BR0312995 A BR 0312995A
Authority
BR
Brazil
Prior art keywords
microcapsules
core
active principle
release
soluble active
Prior art date
Application number
BR0312995-0A
Other languages
English (en)
Inventor
Florence Guimberteau
Catherine Castan
Remi Meyrueix
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of BR0312995A publication Critical patent/BR0312995A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO FARMACêUTICA ORAL SOB A FORMA DE UMA PLURALIDADE DE MICROCáPSULAS, PERMITINDO A LIBERAçãO PROLONGADA DE PRINCìPIO(S) ATIVO(S) POUCO SOLúVEL(IS)". A invenção refere-se às microcápsulas com liberação prolongada de princípios ativos (PA) de pouca solubilidade, constituídas de um núcleo contendo o PA e revestido de uma camada de polímero que controla a liberação do PA. A finalidade é que essas microcápsulas orais de PA pouco solúvel tenham uma película de revestimento de espessura suficiente para assegurar uma permeabilidade controlada e industrialmente reprodutível. Essa finalidade é atingida pelas microcápsulas, de acordo com a invenção, cujo diâmetro médio é inferior a 1000 mícrons, e cuja película de revestimento contém um polímero filmógeno (P1) insolúvel nos líquidos do trato gastrointestinal; um polímero hidrossolúvel (P2); um plastificante (PL); e eventualmente um agente tensoativo (TA) lubrificante, que são caracterizadas pelo fato de sua película de revestimento representar pelo menos 3 % p/p seg, de sua massa total, e seu núcleo conter um PA pouco solúvel e um agente solubilizante (óleo de rícino hidrogenado polioxietilenado) que confere ao núcleo, no qual é incluído, propriedades tais como o comportamento do núcleo sem revestimento em um teste de dissolução TD determinado, é o seguinte: liberação de 80 % do PA em menos de duas horas. A invenção refere-se também às aplicações dessas microcápsulas em galênico.
BR0312995-0A 2002-07-26 2003-07-28 Formulação farmacêutica oral sob a forma de uma pluralidade de microcápsulas, permitindo a liberação prolongada de princìpios(s) ativo(s) pouco solúvel(is) BR0312995A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0209532A FR2842736B1 (fr) 2002-07-26 2002-07-26 Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
PCT/FR2003/002382 WO2004010983A2 (fr) 2002-07-26 2003-07-28 Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)

Publications (1)

Publication Number Publication Date
BR0312995A true BR0312995A (pt) 2005-06-28

Family

ID=30011529

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312995-0A BR0312995A (pt) 2002-07-26 2003-07-28 Formulação farmacêutica oral sob a forma de uma pluralidade de microcápsulas, permitindo a liberação prolongada de princìpios(s) ativo(s) pouco solúvel(is)

Country Status (17)

Country Link
US (1) US8652523B2 (pt)
EP (1) EP1524968B1 (pt)
JP (2) JP5430815B2 (pt)
KR (1) KR20050026515A (pt)
CN (1) CN1678295B (pt)
AT (1) ATE381927T1 (pt)
AU (1) AU2003269067B2 (pt)
BR (1) BR0312995A (pt)
CA (1) CA2493453C (pt)
DE (1) DE60318316T2 (pt)
ES (1) ES2298551T3 (pt)
FR (1) FR2842736B1 (pt)
IL (1) IL166383A0 (pt)
MX (1) MXPA05001077A (pt)
PT (1) PT1524968E (pt)
WO (1) WO2004010983A2 (pt)
ZA (1) ZA200500693B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
CA2480824A1 (fr) 2002-04-09 2003-10-16 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
KR20070044805A (ko) 2004-04-15 2007-04-30 키아스마, 인코포레이티드 생물학적 장벽 투과를 촉진시킬 수 있는 조성물
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
FR2882259A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
EP1850835A1 (fr) * 2005-02-21 2007-11-07 Flamel Technologies Forme pharmaceutique orale de losartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
EP2522343A1 (en) 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
FR2936709B1 (fr) * 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
FR2945947B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
FR2945945B1 (fr) * 2009-05-29 2011-07-29 Flamel Tech Sa Procede de preparation de particules creuses et leurs applications
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
RS56839B1 (sr) * 2012-04-30 2018-04-30 Tillotts Pharma Ag Formulacija leka sa odloženim otpuštanjem
CA2975599A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
AU2016388308B2 (en) 2016-01-20 2022-08-04 Theravida, Inc. Methods and compositions for treating hyperhidrosis
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2020130649A1 (ko) * 2018-12-19 2020-06-25 대화제약 주식회사 Glp-1 유사체를 포함하는 경구투여용 약제학적 조성물
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2313915A1 (fr) 1976-01-26 1977-01-07 Corneille Gilbert Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme
US4321253A (en) 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
HU187215B (en) 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
LU85943A1 (fr) 1985-06-12 1987-01-13 Galephar Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
IT1227899B (it) 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
FI922107A0 (fi) * 1991-05-10 1992-05-08 Faulding F H & Co Ltd Mikrokapselkomposition och foerfarande.
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
JPH0873345A (ja) 1994-09-05 1996-03-19 Terumo Corp 医薬製剤
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
FR2732218B1 (fr) * 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
JPH09188617A (ja) 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
JP2000514059A (ja) 1996-06-28 2000-10-24 シェーリング コーポレイション トリアゾール抗真菌化合物を含む経口組成物
EP0953359A4 (en) 1996-12-19 2001-12-19 Daiichi Seiyaku Co PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
IL162023A0 (en) 1998-03-30 2005-11-20 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
TW407058B (en) 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
EP1117384A1 (en) 1998-10-01 2001-07-25 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
FR2825023B1 (fr) 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
DE60325709D1 (de) * 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
CA2480824A1 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline

Also Published As

Publication number Publication date
PT1524968E (pt) 2008-03-13
FR2842736B1 (fr) 2005-07-22
ATE381927T1 (de) 2008-01-15
US20060165809A1 (en) 2006-07-27
DE60318316D1 (de) 2008-02-07
US8652523B2 (en) 2014-02-18
CA2493453A1 (fr) 2004-02-05
CN1678295A (zh) 2005-10-05
IL166383A0 (en) 2006-01-16
EP1524968A2 (fr) 2005-04-27
JP2006500332A (ja) 2006-01-05
FR2842736A1 (fr) 2004-01-30
CA2493453C (fr) 2012-05-22
DE60318316T2 (de) 2008-12-11
ZA200500693B (en) 2006-07-26
AU2003269067A1 (en) 2004-02-16
EP1524968B1 (fr) 2007-12-26
ES2298551T3 (es) 2008-05-16
JP5430815B2 (ja) 2014-03-05
JP2014005289A (ja) 2014-01-16
KR20050026515A (ko) 2005-03-15
WO2004010983A2 (fr) 2004-02-05
AU2003269067B2 (en) 2009-01-08
MXPA05001077A (es) 2005-06-06
CN1678295B (zh) 2010-04-28
WO2004010983A3 (fr) 2004-04-08

Similar Documents

Publication Publication Date Title
BR0312995A (pt) Formulação farmacêutica oral sob a forma de uma pluralidade de microcápsulas, permitindo a liberação prolongada de princìpios(s) ativo(s) pouco solúvel(is)
WO2004010984A3 (fr) Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os
US9572773B2 (en) Layered drug delivery device
Maheshwari et al. Chitosan encrusted nonionic surfactant based vesicular formulation for topical administration of ofloxacin
CY1109606T1 (el) Βιοδιασπωμενο υμενιο για την απελευθερωση φαρμακου στον οφθαλμο
CA2554052A1 (en) Ternary non-lamellar lipid compositions of structure forming amphiphile, structure swelling amphiphile and dispersion stabilising amphiphile
HUP0301887A2 (hu) Több részecskébżl álló gyógyszerforma, amely legalább két különbözżen bevont pelletformát tartalmaz
EP1832289A3 (en) Compositions and coatings for implantable medical devices
WO2008132710A3 (en) Pharmaceutical nimodipine compositions
CA2595385A1 (en) Pharmaceutical lipid compositions
EP2968401B1 (en) Tinted antiseptic solutions having improved stability
Zaid et al. Development and stability evaluation of enteric coated Diclofenac sodium tablets using Sureteric.
Shenderovich et al. Local sustained-release delivery systems of the antibiofilm agent thiazolidinedione-8 for prevention of catheter-associated urinary tract infections
JP6780412B2 (ja) コーティング組成物ならびにコーティング製剤及びその製造方法
DE60200202D1 (de) Ein Chinolonderivat enthaltendes Arzneimittel und Verfahren zu dessen Herstellung
Elmowafy et al. Polymeric nanoparticles based topical gel of poorly soluble drug: formulation, ex-vivo and in vivo evaluation
Garg et al. Effect of formulation parameters on the release characteristics of propranolol from asymmetric membrane coated tablets
Sangeetha et al. Formulation of sodium alginate nanospheres containing amphotericin B for the treatment of systemic candidiasis
JP6979646B2 (ja) 徐放性癒着防止材
Muschert et al. Improved long term stability of aqueous ethylcellulose film coatings: importance of the type of drug and starter core
ES2173739T3 (es) Forma farmaceutica multiparticular con liberacion programada y pulsada y su procedimiento de preparacion.
KR890007746A (ko) 치환된 디히드로피리딘류의 채널 차단제에 대한 지속적 방출 전달 시스템
CZ302946B6 (cs) Mikrogranule obsahující inhibitor žaludecní protonové pumpy, zpusob jejich prípravy a farmaceutický prostredek je obsahující
ZA202307570B (en) High loading oral film formulation
HUP0101458A2 (hu) Levoszimendánt tartalmazó, szabályozott felszabadulású orális készítmények

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: FLAMEL IRELAND LIMITED (IE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.